Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Related Posts

HIV Drug Resistance to Dolutegravir Among Adults Investigated for Antiretroviral Treatment Failure in Malawi: A 2023 National Cross-Sectional Survey

Kalata NL, Bello G, Pals S, Kabaghe AN, Mkungudza J, Bighignoli B, Panja L, Bilaal W, Kusakale G, Chitenje M, Luhanga M, Zeh C, Kampira[...]

Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn’t

Talishinsky A, Ajijola OA, Salhi RA. Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn't. J Am Heart Assoc. 2025[...]

The Relationship Between HIV Preexposure Prophylaxis Use and Laboratory-Confirmed Bacterial Sexually Transmitted Infection Positivity Among a Diverse, Multi-City Cohort of Sexually Active Sexual and Gender Minorities in the United States

Yonko EA, Tian J, Aminzadeh K, Qian Y, Noori G, Plankey M, Friedman MR, Palella FJ, Jones DL, Wingood G, Sharma A, Dionne JA, Edmonds[...]